BRAF and melanoma: Moreover, the vemurafenib-resistant BRAF-mutant melanomas may acquire dependency on the presence of the targeted drug for their proliferation, such that interruption in administering the BRAF inhibitor may lead to regression of non-lethal drug-resistant tumors (100).